Introduction
Gene therapy for respiratory disease has so far focused on cystic fibrosis (CF). Clinical trials, both in the nasal and lower airway epithelium, have demonstrated proofof-principle that correction of the underlying bioelectric defect can be achieved in vivo in man. [1] [2] [3] [4] [5] However, it is likely that the level of gene transfer efficiency currently available is insufficient to provide clinical benefit. Two broad ways to overcome this are to increase the efficiency of the vector system, or to overcome the biological barriers inherent in the airways. With regard to the latter, we 6 and others [7] [8] [9] [10] have demonstrated a number of extra and intracellular barriers to gene transfer in the respiratory epithelium. In particular, the normal mucus overlying the airway epithelium has an important inhibitory effect on gene transfer efficiency. In this study we have assessed ways in which this barrier may be overcome.
Two broad approaches to altering this mucus barrier can be envisaged, namely a change in its composition or a reduction in amount. With regard to the former, a study of gene transfer to intestinal stem cells showed some improvement with the mucolytic agents diothiothreitol and N-acetylcysteine. 11 A relatively new mucolytic agent, Nacystelyn, a lysine salt of N-acetylcysteine, has the ability to break both hydrogen and disulphide bonds, both of which are important in maintaining the threedimensional structure of mucus. This agent has been shown to alter the rheological properties of mucus, 12, 13 and also to alter the viscosity of CF sputum, either alone or in combination with recombinant human DNAse in vitro.
14 Nacystelyn thus represents a potential candidate for altering the composition of the airway mucus barrier. With regard to inhibition of mucus secretion the anticholinergic agent atropine has, for many years, been the drug of choice as a pre-operative agent but has now largely been superceded by drugs such as glycopyrrolate which have an improved efficacy/toxicity window. 15 Thus glycopyrrolate represents a second potentially useful agent for enhancing gene transfer efficiency.
We have previously described an ex vivo sheep tracheal model in which native tissue is briefly maintained at an air-liquid interface, the tissue retaining its normal barrier functions, including mucociliary clearance and mucus production. 6 The sheep tracheal tissue can be readily depleted of mucus by physical means and this assay provides a useful model in which to assess the effect of mucus alterations on gene transfer efficacy. Clearly such ex vivo results may not mimic the in vivo setting and we have therefore used both this sheep model as well as the mouse nose in vivo, a well-established system to assess gene transfer efficacy. Studies were carried out with both cationic liposomes and a cationic polymer, using reporter genes as an assay for gene transfer efficacy. Finally, the effect of mucus alterations were assessed in the CF mouse nose by measurement of chloride transport.
Results

Normal airway mucus is a barrier to both linear polyethylenimine (L-PEI)-mediated and p-ethyldimyristoylphosphatidyl choline cholesterol (EDMPC:Chol)-mediated gene transfer
Gene transfer was assessed in an ex vivo sheep tracheal epithelium model maintained at an air-liquid interface. Tissues were either studied in their native mucus covered state (approximately 75% coverage) or mucus depleted by overnight shaking (approximately 25% mucus coverage). 6 Mucus covered or depleted tissues were transfected with pCF1-CAT complexed with either EDMPC:Chol or L-PEI. For both the cationic liposome and the cationic polymer, significant (P Ͻ 0.001) increases in gene expression were observed following mucus depletion, with little or no expression being seen in mucus covered tissues (Figure 1) .
Similar results were obtained with differing N/P ratios and PEI molecules (25 and 800 kDa). EDMPC:Chol/DNA Gene Therapy at 1:4 (w/w) and L-PEI at N/P = 5 were chosen for further investigation as the optimal ratios for gene transfer efficiency in mucus-depleted tissues. Figure 2 shows the effect of Nacystelyn on both (a) EDMPC:Chol and (b) L-PEI-mediated gene transfer in the sheep tracheal ex vivo model, using mucus covered tissues. Using either gene transfer agent, Nacystelyn induced a dose-related increase in gene transfer efficiency with optimal concentrations around 300-400 mm for either vector (P Ͻ 0.01 compared with control).
Addition of Nacystelyn immediately before complex addition significantly increases gene expression ex vivo using either delivery agent
Determining the active component of the Nacystelynmediated increase in gene expression
Nacystelyn is the lysine salt of N-acetylcysteine. To assess which is the biologically active component, N-acetylcysteine or lysine at a range of concentrations (100-900 mm) were applied to the apical surface of mucus covered tissues before transfection. Figure 3 shows the effect of N-acetylcysteine on both EDMPC:Chol (a) and L-PEI (b)-mediated gene transfer. For both agents there was a doserelated increase in gene expression, with maximal expression around 300-400 mm (P Ͻ 0.001 compared with control). Lysine (300, 400 and 500 mm) showed no significant increase in gene expression above control with either cationic liposome or cationic polymer (data not shown). We therefore conclude that N-acetylcysteine is the active component of the Nacystelyn increase in gene expression.
EDMPC:Chol but not L-PEI induces gene transfer in the mouse nose
EDMPC:Chol produced low levels of expression (maximum 4.3 × 10 −7 CAT U/g protein) in four of 15 mice using 240 g DNA, in one of five mice using 120 g DNA and in none of six mice using 60 g DNA.
Values were approximately one log lower than those produced using 80 g of DNA complexed with Genzyme lipid 67 (GL67), the cationic liposome used in our recently reported lung trial in CF patients. 5 L-PEI was complexed with 80 g of pCF1-CAT plasmid in a 150 l of 5% sucrose solution at an N/P ratio of 5. At this concentration, there was precipitation of complexes, which resulted in blockage of the fine perfusion catheters. This problem was compounded by higher DNA concentrations (120 or 160 g of DNA) and no DNA concentration or alterations in N/P ratio tested produced detectable CAT activity. Further experiments, therefore, focused on using EDMPC:Chol in vivo in the mouse nose. 
Pretreatment with Nacystelyn or glycopyrrolate increases gene expression in the mouse nose in vivo
Mouse noses were perfused with Nacystelyn immediately before perfusion with complex, rather than using co-administration, to exclude possible in vitro interaction between the two. As shown in Figure 4 , Nacystelyn pretreatment resulted in a significant increase in gene expression with optimal effects at between 50 mm (P Ͻ 0.001) and 100 mm (P Ͻ 0.01). We also assessed the effect of Nacystelyn (100 mm) added at the same time as the EDMPC:Chol/DNA complexes (240 g of pCF1-CAT). This resulted in a marked inhibition of gene expression (2.7 ± 3.6 × 10 −7 CAT U/g protein) compared with Nacystelyn pretreatment.
Glycopyrrolate (50 g/kg) was given as an intramuscular injection 1 h before perfusion of complexes. A significant (P Ͻ 0.01) increase in gene expression was noted at all concentrations tested when compared with untreated animals ( Figure 5 ). No toxic effects were seen as a result of administration with either Nacystelyn or glycopyrrolate in any animal.
To assess whether the combination of Nacystelyn and glycopyrrolate had a synergistic effect, mice were pretreated intramuscularly with glycopyrrolate (50 g/kg) approximately 30 min before perfusion with 100 mm Nacystelyn. Immediately afterwards EDMPC:Chol/DNA complexes were perfused on to the mouse nose so that complex perfusion began approximately 1 h after glycopyrrolate pretreatment. Gene expression levels were significantly reduced (3.0 ± 2.9 × 10 −6 CAT U/g protein) when compared with pretreatment with 100 mm Nacystelyn alone (3.9 ± 1.9 × 10 −5 CAT U/g protein) or 50 g/kg glycopyrrolate alone (2.1 ± 0.7 × 10 −5 CAT U/g protein).
Perfusion of the noses of
.0 mV. CF mice were subsequently either pretreated with glycopyrrolate (50 g/kg) or with Nacystelyn (100 mm) before perfusion with EDMPC:Chol/pCF1-CFTR. Fortyeight hours later, the response to low chloride perfusion was reassessed. Figure 6 shows the result in individual animals. Pretreatment with Nacystelyn did not significantly change the low chloride response (⌬V = 1.1 mV depolarisation), while a small but significant (P Ͻ 0.05) change towards normal values (⌬V = 1.5 mV depolarisation) was observed after glycopyrrolate pretreatment. However, a similar change was also seen when the diluent for the EDMPC:Chol/pCF1-CFTR complex (water) was nasally perfused following glycopyrrolate (⌬V = 1.6 mV depolarisation).
Discussion
Gene transfer to airway epithelium has been shown to be limited by the presence of extra-cellular barriers such as CF sputum, 16 CF bronchial secretions, 17 the glycocalyx 18 and by airway mucus. 6 These factors likely make a major contribution to the low gene transfer efficiencies seen in CF clinical trials to date. We 16 previously showed that sputum from CF patients markedly inhibited gene transfer efficiency mediated by synthetic vectors and adenovirus. The importance of mucus in limiting gene transfer efficiency has previously been addressed by us and others. Thus, cationic lipids, but not viral vectors, are inhibited by mucus and a significant increase in gene expression was seen when tissues were mucus depleted following overnight shaking. 6 Sandberg et al 11 showed that pretreatment with dithiothreitol and N-acetylcysteine significantly improved access to intestinal villi. The aim of the present study was to assess whether clinically used agents known to alter mucus properties could increase gene expression, as a precursor to a clinical trial.
In keeping with our previous work using lipid GL-67, 6 two other gene transfer agents (EDMPC:Chol and L-PEI) are also inhibited by mucus suggesting this barrier is rate-limiting for a wide spectrum of synthetic vectors despite their different physical/chemical structure and charge ratio. These results were expected due to the presence of positive charges on the cationic lipid which can interact with the negative residues present on mucus, thus limiting the bio-availability of complexes. The higher transfection efficiency observed with EDMPC: Chol compared with L-PEI could be due to its overall negative charge. This would allow EDMPC:Chol/DNA complexes to cross the mucus barrier more easily. However, the transfection efficiency is still very low. Furthermore, complexes of PEI with different molecular weights at N/P ratios giving an overall negative charge to the complex were also unable to overcome the mucus barrier (data not shown). This suggests that together with charge, molecular weight may play a role. It has previously been shown that mucus acts as a physical barrier for molecules greater than 17 kDa molecular weight. 19 Nacystelyn is a lysine salt of N-acetylcysteine and has the ability to break both hydrogen and disulphide bonds, both of which are important in maintaining the threedimensional structure of mucus. Nacystelyn has been shown to increase ciliary beat frequency in the frog palate model and increase tracheal mucus velocity in healthy mongrel dogs. 12, 13 It also shows efficacy in altering the viscosity of CF sputum either alone, or in combination with recombinant DNase in vitro.
14 In our ex vivo sheep trachea model, Nacystelyn (400 mm) produced transgene expression similar to the effect of mechanical mucus depletion. The active component of Nacystelyn was Nacetylcysteine. Although this agent is sometimes used clinically, it often produces pulmonary bronchoconstriction due to the fact that a 100 m solution has a pH of 4 whereas with Nacystelyn the same concentration produces a pH of 6.5 and appears not irritant. In the case of the latter, increasing the concentration does not produce a further change in pH and thus it was used in further studies. 20 For our in vivo experiments, the mouse nose was chosen as the site to evaluate the efficacy of Nacystelyn and glycopyrrolate to increase gene transfer efficiency. The selection of the in vivo 'test-bed' for such studies is problematic. Murine lower airways are different from human airways being rich in Clara cells and unable to secrete large amounts of mucus because of the limited number of submucosal glands. 21 On the other hand, the mouse nose is anatomically similar to the human nose and has the important advantage that studies can be extrapolated to CF mice to assess CFTR-dependent changes. In preliminary studies we also assessed whether the ferret lung would provide a better model, given its well-recognized capacity for mucus secretion from submucosal glands. 22 However, in the unstimulated state we observed (using scanning electron microscopy) coverage of only 20% of conducting airway surface by mucus. The dose-related increase in reporter gene expression in the mouse nose produced by Nacystelyn and glycopyrrolate and the advantage of subsequently being able to assess CFTR function were important factors in our choice of this site and species.
To assess whether these changes were sufficient to influence correction of CFTR function, we pretreated CF mice with our mucolytic agents before administering EDMPC:Chol complexed with a plasmid carrying the CFTR gene. Reduction of mucus was obtained either by changing its composition (with Nacystelyn) or by reducing its amount (with the anticholinergic agent glycopyrrolate). Compared with diluent controls no significant change in the key low chloride response was seen. Similar experiments using GL-67 also did not demonstrate substantial improvements in bioelectrical correction (data not shown). Combining glycopyrrolate and Nacystelyn produced an inhibitory effect on CAT expression. Whether this relates to interaction of the agents at a common site of action in vivo is unclear. As a by-product of these studies the data suggest that in the mouse nose, CAT expression levels of approximately 4 × 10 −5 CAT U/g protein as a surrogate marker for CFTR expression is insufficient to correct the CF chloride defect. The successful detection of CAT but not CFTR correction may relate to different assay sensitivities or differing amounts of protein produced. This may provide a useful benchmark for other reporter gene studies aimed at CF.
In conclusion, the results suggest that current clinically used agents which affect mucus composition or quantity are insufficient by themselves to overcome the many hurdles facing respiratory gene transfer. These include the low endocytic rate of the apical membrane, escape from the endosomal compartment and uptake across the nuclear pore complex. New strategies to overcome these barriers 23 are being developed. Together with mucus depletion, these may form a package of incremental gains which could eventually overcome the lack of efficiency seen with nonviral gene transfer agents. An alternative strategy may be the use of new gene transfer agents which have been shown to be able to overcome many of the extra-and intra-cellular barriers present in airway epithelia. 24 
Materials and methods
Reagents
All reagents were obtained from Sigma (Poole, UK) unless otherwise stated, and were of AnalaR grade or best available.
Preparation of L-PEI/DNA and EDMPC:Chol complexes
Linear 22 kDa PEI (Euromedex, Souffelweiersheim, France) was used as a 100 mm (4.5 g/l) aqueous stock solution. Preparation of L-PEI/DNA complexes was carried out as previously described. 25 Briefly, the desired amount of pCF1-CAT and L-PEI were each diluted in 5% sucrose solution, vortexed and mixed after 10 min. Complexes with L-PEI were characterized on the basis of their PEI nitrogen per DNA phosphate ratio (N/P). DNA was complexed with L-PEI at N/P = 5 in 5% sucrose solution, unless otherwise stated, then incubated at room temperature for 20 min to allow complexation. EDMPC:Chol complexes were prepared as previously described. 26 Briefly, EDMPC was mixed in a 1:1 molar ratio with cholesterol, then mixed with DNA such that the DNA:lipid ratio was 4:1 by mass and the final DNA concentration, 2 mg/ml. This complex was stored at 4°C until use.
Sheep tracheal ex vivo model
Preparation of the sheep tracheal model and mucus depletion of the epithelium were carried out as previously described. 6 Briefly, the epithelial layer from sheep tracheae was dissected into approximately 0.5 cm 2 pieces, and placed at an air-liquid interface. Mucus depletion was carried out by placing the sheep tracheae on a shaking platform in a waterbath at 37°C overnight.
Treatment of sheep tracheae with mucolytic agents N-acetylcysteine, lysine and Nacystelyn (Galephar SMB, Brussels, Belgium) were prepared in Dulbecco's modified Eagle's medium (DMEM) with 50 g/ml gentamycin and 1× antibiotic/antimycotic solution. When necessary pH was brought to neutrality with NaOH. Before transfection, 20 l of mucolytic agent at the appropriate concentration were applied to the apical surface of the mucuscovered tissues just before transfection with either L-PEI/DNA (15 g DNA) or EDMPC:Chol/DNA (10 g DNA) in 15 and 10 l, respectively.
Chloramphenicol acetyl transferase (CAT) reporter gene assay
Forty-eight hours after transfection, tissue lysates were prepared and assayed for CAT expression according to previously described methods. 27 For all transfections values are expressed as CAT units/g protein as previously described.
Mouse in vivo nasal perfusions
Animals: Non-CF mice (Balb/C, male, 6-10 weeks of age, Harlan, Oxon, UK) and CF mice (Cftr tm1Cam or Cftr
G551D
because of the limited availability of CF mice) of mixed gender and approximately 10 weeks of age were used. Animals were housed under identical conditions except that CF mice had an osmotic polyethylene glycol-based laxative (Klean Prep, Norgine Limited, Middlesex, UK) added to their drinking water as well as a low-fibre diet (Special Diet Services, Essex, UK) to prevent intestinal obstruction.
Reporter gene studies: Nacystelyn solutions (150 l final volume) were perfused over approximately 30 min before perfusion of lipid/DNA complexes. Glycopyrrolate (Robinul Injection; Anpharm Ltd, Roscrea, Ireland) was administered by intramuscular injection 60 min before perfusion with complexes. Lipid/DNA complexes were administered as previously described. 24 Briefly, a fine-tip polyethylene catheter was placed 5 mm within the nasal cavity and 120 l of the lipid/DNA solution perfused at a rate of 5 l/min using a peristaltic pump. Mice were killed 48 h after transfection, nasal turbinates removed, homogenised and assayed for CAT activity.
CFTR gene studies:
The in vivo nasal potential difference (PD) of the CF mice was determined 1 week before gene transfer, as previously described. 28 Briefly, a sequence of (1) HEPES-containing Kreb's solution (HK) plus amiloride and (2) low-chloride HK plus amiloride was perfused into the nasal cavity of CF mice at a rate of 21 l/min using a peristaltic pump. The effects of perfusion of low-chloride HK solution were assessed after 5 min. Treatments with Nacystelyn, glycopyrrolate and EDMPC:Chol/CFTR complexes were carried out as described for Balb/C mice. Forty-eight hours after gene delivery, low chloride responses were once again determined.
Statistics
The data are presented as mean ± s.e.m., where n refers to number of sheep (for ex vivo work) or animals (for in vivo work). The Mann-Whitney U test was used to compare means and the null hypothesis was rejected at P Ͻ 0.05.
